TNX-1840

TNX-1840 is an investigational live virus vaccine candidate for COVID-19 based on Tonix’s recombinant pox viral vector platform[1][13][15]. The vaccine is designed to express the spike protein from the Omicron variant of SARS-CoV-2[9]. The platform utilizes a live recombinant poxvirus vector—specifically, horsepox virus—to deliver the target antigen[15]. This approach is intended to stimulate both humoral and cellular immune responses, potentially offering broad and durable protection against COVID-19. While development progresses, current public information emphasizes its status as a clinical candidate rather than a marketed product.